Search by Medical Condition
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for Hematologic Neoplasms
- B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
- Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion
- Study of AZD9829 in CD123+ Hematological Malignancies
- IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- ATG Plus Low-dose PT-Cy for GVHD Prevention
- Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation
- PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM
- A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
- Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
- Research Development(RD)13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7(CD7)+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)
- RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL
- Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies
- Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy
- Post-Transplant Cyclophosphamide in Patients Aged >/=70 Years Undergoing Haploidentical Transplant
- First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
- DETERMINE Trial Treatment Arm 4: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations
- A Study of Shengxuening Tablet in the Treatment of Chemotherapy-related Anemia in Hematologic Tumors
- DETERMINE Trial Treatment Arm 3: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.
- DETERMINE Trial Treatment Arm 1: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers
- DETERMINE Trial Treatment Arm 5: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
- Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
- HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
- The Study of ICP-248 in Patients With Mature B-cell Malignancies
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
- A Phase I, Double Blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study
- CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL
- Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies
- A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension
- A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)
- A Study of PR2527 in Participants With Relapsed/Refractory Hematologic Malignancies
- Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
- HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
- Switched Memory B-cells as a Marker for Humoral Immune System Recovery in Patients With Secondary Antibody Deficiency Due to Hematological Malignancies
- Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects
- Study of BLU-263 in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies
- A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
- A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies
- Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
- Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
- Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
- Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
- Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies
- Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT.
- Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors
- Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Bone Marrow Transplantation Followed by GVHD Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV (PLWH)
- CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies
- Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
- Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies
- Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome
- Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
- Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
- Phase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
- A Phase 1 Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
- First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies
- A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)
- A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies
- Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies
- SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma.
- Venetoclax Basket Trial for High Risk Hematologic Malignancies
- A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)
- A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies
- A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies
- CXCR4-targeted PET/CT Imaging in Hematological Malignancies
- Multi Cohort Study of Tazemetostat in Combination With Various Treatments For R/R Hematologic Malignancies
- Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
- Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
- Comparsion of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis
- Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
- A Study of PRT1419 Injection in Patients With Relapsed/Refractory Hematologic Malignancies
- A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy
- Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
- Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
- CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients
- A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies
- A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
- COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
- A Study of TQB3820 in Patients With Hematological Malignancies
- (Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis
- The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer
- Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
- A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
- Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)
- GSL Synthetase Inhibitor or in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor
- Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants
- Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia
- FHD-286 in Subjects With Advanced Hematologic Malignancies
- A Study of DT2216 in Relapsed/Refractory Malignancies
- A Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies
- Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies
- Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers
- GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
- Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients
- Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies
- Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions
- Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
- A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
- Efficacy and Safety of Micafungin for Injection in Prevention and Treatment of Fungal Infection in Hematological Tumors
- Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)
- CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies
- A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
- A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies
- SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
- Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
- Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation
- Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies
- LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer.
- Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma
- GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide
- Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
- A Study of GFH009 in Patients With Hematologic Malignancies
- Ruxolitinib and Decitabine for High Risk Hematological Malignancies
- A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma
- Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
- A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies
- A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
- RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies
- A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat
- Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies
- Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies
- HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
- Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH Trial)
- Effects of Parenteral Nutrition in HSCT
- A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
- A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies
- Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
- Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)
- Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
- Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
- Safety and Preliminary Efficacy of ATG-017 Monotherapy in Advanced Solid Tumors and Hematological Malignancies
- Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects
- A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies
- CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
- A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
- Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
- Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies
- GM-CSF With Post-Transplant Cyclophosphamide
- A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
- A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
- Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
- The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies
- Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
- Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
- Study to Evaluate CCS1477 in Haematological Malignancies
- Nutritional and Physical Exercise Intervention in Older Patients With Malignant Hemopathies
- Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
- BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)
- Dual PD-1 and JAK2 Inhibition in Hematological Malignancies
- MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
- Optimizing PTCy Dose and Timing
- Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT
- Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant
- Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies
- CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant
- A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
- RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma
- Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy
- A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.
- A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
- VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
- CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
- TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
- Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
- Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
- Durvalumab and Tremelimumab for Pediatric Malignancies
- Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
- A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers
- Evolution of Thromboelastography During Tranexamic Acid Treatment
- Early Palliative Care for Patients With Haematological Malignancies
- A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
- A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers
- A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies
- Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT
- Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
- 2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
- Compassionate Use Study of Tenalisib (RP6530)
- PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant
- Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation in Patients With Hematologic Malignancy
- A Study of TAK-981 in Participants With Relapsed/Refractory Solid Tumors or Non-Hodgkin Lymphoma (NHL)
- Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
- Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies
- (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
- A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
- A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
- A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
- APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
- T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia
- Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
- A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies
- Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers
- Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH)
- Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
- Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant
- Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole
- Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
- Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant
- Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies
- Safety and Efficacy Evaluation of IM19 Cells
- A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies
- Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing HSCT
- GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
- Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
- Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
- A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
- Study of Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Hematopoietic Malignancies Including Those That Are Challenging to Engraft
- A Study of Nemtabrutinib (MK-1026) (ARQ 531) in Participants With Selected Hematologic Malignancies
- Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
- Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)
- Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation
- Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
- TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia
- Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults
- Venetoclax and Ibrutinib in Treating Participants With High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
- Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies
- A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
- Extended Analysis for Leukemia/Lymphoma Treatment
- Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies
- A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
- A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity
- Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
- Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies
- A Study of DEcolonization in Patients With HAematological Malignancies (DEHAM)
- Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients
- A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
- Study of IV CBL0137 in Previously Treated Hematological Subjects
- Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation
- A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy
- Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
- Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer
- T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation.
- Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
- Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
- Phase I Trial of BAY1251152 for Advanced Blood Cancers
- Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard Umbilical Cord Blood in Patients With Leukemia, Lymphoma, and Myelodysplastic Syndrome (MDS)
- Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
- Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
- An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
- A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)
- A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
- Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)
- Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
- To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
- CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies
- Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia
- A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors
- Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study
- Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
- Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens
- Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT
- A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies
- Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant
- Allogeneic Stem Cell Transplantationin Relapsed Hematological Malignancy: Early GVHD Prophylaxis
- Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
- Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies
- Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
- Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
- Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
- A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders.
- Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
- Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies
- Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy
- Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
- Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
- CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies
- Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
- An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
- An Open-label Phase II Study of Lorvotuzumab Mertansine
- Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
- A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations
- A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area
- A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers
- ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
- Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
- Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
- A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
- Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies
- Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
- Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies
- A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies
- Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies
- Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
- Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies
- Study Evaluating Venetoclax in Subjects With Hematological Malignancies
- Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
- Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer
- A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies
- Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
- Pasireotide in Prevention of GI Toxicity
- Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen
- Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
- Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies
- BGJ398 for Patients With Tumors With FGFR Genetic Alterations
- Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO
- Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
- Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy
- Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
- Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
- Trial of Myeloablative Conditioning & Transplantation of Partially Human Leukocyte Antigen (HLA)-Mismatched Marrow With Post-transplant Cyclophosphamide for Peds Pts w/ Hematologic Malignancies
- Treg Cells for AGVHD in Non-myeloablative UCB Transplant
- Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies
- Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
- PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)
- Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
- Safety of Romiplostim (Nplate®) Following UCBT
- A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
- Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1
- Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
- LGX818 for Patients With BRAFV600 Mutated Tumors
- A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies
- Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
- A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
- Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant
- Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
- Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
- Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
- Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies
- Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)
- MEK162 for Patients With RAS/RAF/MEK Activated Tumors
- Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
- Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation
- Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis
- Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain
- An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate
- A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies
- Cologne Cohort of Neutropenic Patients (CoCoNut)
- Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
- Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
- Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
- Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator
- Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
- Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
- Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
- Efficacy Study of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation
- Phase II Maraviroc for GVHD Prevention
- Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
- Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
- Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation
- Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation
- Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies
- A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors
- Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies
- CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
- Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
- Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
- Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
- Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies
- T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
- Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
- A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
- Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens
- Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation
- A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
- Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib
- Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
- Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
- Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation
- A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
- Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation
- Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
- Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens
- Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
- Phase 2 Study of SAR302503 in Patients With Myelofibrosis
- Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
- Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
- Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
- A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors
- Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors
- Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
- Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
- A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
- Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
- Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
- Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)
- Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
- Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
- Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
- A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
- A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies
- AMG 319 Lymphoid Malignancy FIH
- Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies
- Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
- Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies
- Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies
- Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
- Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
- Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
- Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
- Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
- Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
- A Dose-escalation Study in Subjects With Advanced Malignancies
- Dose Escalation of IPI-493 in Hematologic Malignancies
- Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
- Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
- Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies
- T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
- Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy
- Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)
- 4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies
- HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
- ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
- Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
- A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies
- Dose-range Finding Treosulfan-based Conditioning
- Observational Study Investigating the Response Rate of Itraconazole Injection in Treating Immunocompromised Patients
- Anidulafungin in Patients With Hematologic Malignancies
- Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy
- Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies
- Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants
- Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
- Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
- Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy
- Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
- Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy
- Trial of Pimasertib in Hematological Malignancies
- A Study Of PF-04449913 In Select Hematologic Malignancies
- Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
- Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
- Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
- Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation
- Extracorporal Photopheresis Pilot Study
- Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies
- Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
- Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies
- Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer
- Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders
- A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation
- Pharmacologic Optimization of Voriconazole
- Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?
- Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.
- Repeat Dose Safety Study for Compound to Treat Hematologic Cancer
- FTS Study in Patients With Advanced Hematologic Malignancies
- Study of Epidermal Growth Factor on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies
- Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies
- A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies
- A Study of BMS-863233 in Patients With Hematologic Cancer
- Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
- Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
- Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies
- Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors
- Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
- A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
- Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies
- Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
- Infusional C-myb ASODN in Advanced Hematologic Malignancies
- Trial Of Double Umbilical Cord Blood Transplantation
- Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
- Allogeneic Hematopoietic Stem Cell Transplantation
- A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)
- A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma
- Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
- A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
- Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma
- Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies
- Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
- Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
- Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies
- Study of MLN8237 in Participants With Advanced Hematological Malignancies
- Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies
- T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
- INCB018424 in Patients With Advanced Hematologic Malignancies
- Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies
- Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
- Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies
- Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors
- A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.
- A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
- Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings
- A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy
- Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
- Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
- A Phase I Trial of ZIO-101 in Hematologic Cancers
- Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
- Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases
- Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies
- Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)
- Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen
- Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients
- Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies
- Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
- Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support
- A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
- Intermittent Use of Aerosolized Ribavirin for Treatment of RSV
- Phase II Trial of Pentostatin and Targeted Busulfan
- A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT
- Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
- Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients
- A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589
- Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
- VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands
- ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.
- Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies
- Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
- Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
- A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative
- Voraxaze for Delayed Methotrexate Clearance
- Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
- Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy
- A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies
- A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
- Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.
- Rituximab for Prevention of Chronic GVHD
- Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
- Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation
- A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies
- Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
- Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
- Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies
- Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
- Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
- Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
- A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)
- G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome
- Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies
- Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies
- Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients
- Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
- Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies
- Allogeneic Transplantation From Related Haploidentical Donors
- Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies
- Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma
- Stem Cell Transplant for Hematological Malignancy
- Stem Cell Transplantation for Hematological Malignancies
- Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell Transplantation: a Pharmacokinetic Study
- Stem Cell Transplantation for Patients With Hematologic Malignancies
- Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
- Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation
- HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
- Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies
- Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation
- Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies
- Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation
- MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies
- Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
- Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
- A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
- STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors
- Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
- OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies
- T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
- Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
- 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies
- Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
- VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
- Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies
- Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
- A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation
- Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
- Stem Cell Transplant for Hematologic Diseases
- Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
- A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
- Study of ABT-751 in Patients With Refractory Hematologic Malignancies
- Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma
- IUdR/BUdR Cell Cycle Labelling
- Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy
- Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
- Clofarabine in Chronic Lymphocytic Leukemia
- Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
- Non-Ablative Allo HSCT For Hematologic Malignancies or SAA
- Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
- Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer
- Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer